



Supplementary Fig. 2. Survival rates of non-DM, DM and DM-HF zebrafish. (a) Kaplan-Meier survival analysis of non-DM, DM, and DM-HF zebrafish larvae. (b) Survival rate at 8 and 9 dpf (n = 96-120 per group). All groups were tested under the same conditions, and the graphs are shown to Fig. 1 and Supplementary Fig. 2. Data are presented as the mean ± standard deviation and each dot represents the value of each experiment. ****p<0.0001 vs. indicated group.




Supplementary Fig. 3. Defect of swim bladder in high molarity sotagliflozin treated DM-HFrEF zebrafish. Relative swim bladder size in DM-HF zebrafish treated with 25 μ M empagliflozin or sotagliflozin (n = 6 per group). Data are presented as mean \pm standard deviation and each

dot represents the value of each zebrafish larva. ** p < 0.01 vs. indicated group.




 $Supplementary\ Fig.\ 4.\ Pericardial\ edema\ and\ uninflated\ swim\ bladder\ in\ high\ dose\ sotagliflozin\ treated\ HF\ induced\ non-DM\ zebrafish.\ (a)$

Representative morphological images. The pericardial edema is indicated by a black arrow, and uninflated swim bladder is indicated by a white arrow. (b) Relative swim bladder size in non-DM with HF zebrafish treated with 1.25 μ M empagliflozin or 25 μ M sotagliflozin (n = 7-11 larvae per group). Data are presented as mean \pm standard deviation and each dot represents the value of each zebrafish larva. ** p < 0.01, *** p < 0.001 vs. indicated group.




of Tg (myl7:EGFP) zebrafish heart with a green fluorescent protein (GFP). (**b**) Ventricular fractional shortening calculated based on fluorescent images. (n=14-17 per group). (**c**) Representative blood flow graphs. (**d**) Standard deviation of beat-to-beat interval analyzed based on blood flow (n=12-15 per group). Data are presented as mean \pm standard deviation and each dot represents the value of each zebrafish larvae. ****p

< 0.0001 vs. indicated group.




Supplementary Fig. 6. Expression of heart failure marker and glucose metabolism-related genes in DM-HF zebrafish treated with empagliflozin or sotagliflozin. (a) Relative mRNA expression of nppb (b) ins and (c) pckl (n = 8 per group). Each group had 8 samples, with 10 larvae per sample. Data are presented as mean \pm standard deviation and each dot represents the value of each sample. * p < 0.05, *** p < 0.01, ***

p < 0.001, **** p < 0.0001 vs. indicated group.




Supplementary Fig. 7. Orientation of the zebrafish NHE1 structural model for molecular docking analysis *in silico*. Orientation strategy of the zebrafish NHE1 structure prediction model for molecular docking analysis of empagliflozin, sotagliflozin, cariporide and D-glucose.



 $\textbf{Supplementary Fig. 8. Intracellular H+ concentration in empagliflozin or sotagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the expression of the empagliflozin or sotagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin or sotagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin or sotagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagliflozin treated cells. pHrodo Red AM for intracellular H^{+} (note that the empagl$

= 15-34 samples per group). Data are presented as mean \pm standard deviation and each dot represents the value of each sample. * p < 0.05, *** vs.

HG group.



Supplementary Fig. 9. Intracellular Na⁺ and Ca²⁺ concentrations treatment with empagliflozin or sotagliflozin in a dose-dependent manner. Measurement of intracellular Na⁺, and Ca²⁺ for the analysis of the NHE1 functional inhibitory effect of empagliflozin or sotagliflozin. (a and b) SBFI AM for intracellular Na⁺, and (c and d) Fluo-4 AM for intracellular Ca²⁺ (n = 6-8 samples per group). Data are presented as mean \pm standard deviation and each dot represents the value of each sample. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. HG group.

0.0850
0.0850
0.4249
2.1247
10.6235